The DOI matches its Crossref record.
The physiological function of drug-transporting P-glycoproteins
Open accessAbstract
The mammalian drug-transporting or mdr1-type P-glycoproteins can extrude a range of structurally diverse, toxic xenobiotic compounds from cells. Our analysis of knockout mice lacking one or both of the mdr1-type P-glycoproteins indicates that a major function of these proteins is the protection of organisms against many of the toxic xenobiotics to which they can potentially be exposed in nature. P-glycoprotein confers protection by limiting the uptake of compounds from the gastrointestinal tract, and by stimulating excretion of compounds in the liver, kidney, and intestine. Moreover, P-glycoprotein in the blood-brain barrier and other blood-tissue barriers protects sensitive organs from exposure to toxic compounds that may have entered the bloodstream. Although we cannot exclude additional physiological functions for mdr1-type P-glycoproteins, these are not vital, since the mdr1-deficient mice are viable and fertile, and do not display obvious phenotypic abnormalities other than hypersensitivity to drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
“The AUC (area under the plasma concentration versus time curve) of orally administered taxol was found to be significantly higher in the double knockout mice, indicating that Pgp expression at the intestinal lumen can limit oral drug bioavailabilit”
BackgroundPharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00169-2 · Cited by 1,386
Self-citationMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
Schinkel, A. H., & Jonker, J. W. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.027 · Cited by 1,231
Self-citationP-glycoprotein: from genomics to mechanism
Ambudkar, S. V., Kimchi-Sarfaty, C., Sauna, Z. E., & Gottesman, M. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206948 · Cited by 1,074
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
(2002) · PubMed · Cited by 840
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
Mechanisms of Drug Resistance in Cancer Chemotherapy
Luqmani, Y. A. (2005) · Medical Principles and Practice · doi:10.1159/000086183 · Cited by 651
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Jonker, J. W. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.20.1651 · Cited by 638
Modelling of the blood–brain barrier in drug discovery and development
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2368 · Cited by 618
Intranasal delivery: Physicochemical and therapeutic aspects
Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., & Quay, S. C. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.03.025 · Cited by 598
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations
Lee, G., Dallas, S., Hong, M., & Bendayan, R. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01513-8 · Cited by 539
Ramesh, R., Kozhaya, L., McKevitt, K., Djuretic, I. M., Carlson, T. J., Quintero, M. A., McCauley, J. L., Abreu, M. T., Unutmaz, D., & Sundrud, M. S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130301 · Cited by 440
Kroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response
Evans, W. E., & Johnson, J. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.9 · Cited by 415
Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport
Wright, S. H., & Dantzler, W. H. (2004) · Physiological Reviews · doi:10.1152/physrev.00040.2003 · Cited by 404
Multixenobiotic resistance as a cellular defense mechanism in aquatic organisms
Bard, S. (2000) · Aquatic Toxicology · doi:10.1016/s0166-445x(00)00088-6 · Cited by 392
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
ROLE OF ABCG2/BCRP IN BIOLOGY AND MEDICINE
Krishnamurthy, P., & Schuetz, J. D. (2006) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141238 · Cited by 356
Epothilones: Mechanism of Action and Biologic Activity
Goodin, S., Kane, M. P., & Rubin, E. H. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.001 · Cited by 346
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert-Keil, C., Walker, L. C., & Warzok, R. W. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00005 · Cited by 345
ABC of oral bioavailability: transporters as gatekeepers in the gut
Dietrich, C. G., Geier, A., & Oude Elferink, R. P. J. (2003) · Gut · doi:10.1136/gut.52.12.1788 · Cited by 317
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Drug efflux transporters in the CNS
Sun, H., Dai, H., Shaik, N., & Elmquist, W. F. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00172-2 · Cited by 304
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer
Tang, Y., Wang, Y., Kiani, M. F., & Wang, B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.05.012 · Cited by 265
Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D., & Papadimitriou, C. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.02.011 · Cited by 261
Managing drug-resistant epilepsy: challenges and solutions
Dalic, L., & Cook, M. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84852 · Cited by 258
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Glucocorticoids, developmental ‘programming’ and the risk of affective dysfunction
Seckl, J. R. (2007) · Progress in Brain Research · doi:10.1016/s0079-6123(07)67002-2 · Cited by 245
Yeast ATP-Binding Cassette Transporters Conferring Multidrug Resistance
Prasad, R., & Goffeau, A. (2012) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092611-150111 · Cited by 221
Boyer, J. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00519.x · Cited by 124
Usansky, H. H., Hu, P., & Sinko, P. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.017483 · Cited by 29
Lochman, L., Kahiya, E. T., Saade, B., Smutný, T., Tebbens, J. D., Pávek, P., & Bernhauerová, V. (2025) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1012886 · Cited by 3
Metadata
- Authors
- Schinkel, A. H.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 1997-06
- Volume
- 8
- Issue
- 3
- Pages
- 161-170
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2090910729
- Cited by
- 458
- References
- 0
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.